International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1942-1947 www.ijprajournal.com ISSN: 2456-4494

Review on Paroxetine Its Pharmacokinetic and Pharmacodynamic Parameters

Kumaran S*, [1]Deepthi D Kini, [2]C Sreedhar, [3]Sreenivasa Rao, [4]Harsha K Tripathy, [5]Manju S V, [6]K Manogna

Rajiv gandhi university of health sciences, bangalore, karnataka
Karnataka college of pharmacy, bangalore, karnataka

Submitted: 05-06-2022 Revised: 18-06-2022 Accepted: 27-06-2022

ABSTRACT:
Paroxetine is a powerful first-line- line inhibitor of serotonin reuptakein a sensory neuron. Paroxetine is a very well antidepressant that is applied in therapeutics around the world. It may have the highest action on serotonin reuptake inhibition when contrasted to otherSSRIs. Emotional disturbances, Delayed stress syndrome, premenstrual dysphoric disorder such as depression and anxiety, and migraine are all treated with it. The most effective inhibitor of serotonin reuptake is paroxetine, a phenylpiperidine analog (5-hydroxytryptamine, 5-HT). A selective serotonin reuptake inhibitor is an anti-anxiety that belongs to a group of medications (SSRI). Chemical name of paroxetine: (3S-trans) -3-[(1,3-benzodioxol-5-yloxy) methyl] -3-[(1,3-benzodioxol-5-yloxy) methyl] -4-(4-fluorophenyl) -hydrochloride -piperidine/ (-) -(3S,4R) -(4-(p-fluorophenyl) -3-[[3,4-(methylenedioxy)phenoxy]methyl] -3-[[3,4-(methylenedioxy)phenoxy]methyl] piperidine.

KEYWORDS: Paroxetine, Pharmacokinetic properties, Pharmacodynamic properties.

I. INTRODUCTION:

Depression(1) is a common syndrome. Even with medication, just around 70% of people will respond to antidepressant pharmaceutical therapy in a timely basis and heal from their depression. Insomnia(inability to sleep) such as a falling off in slow-wave sleep, an improvement in Rapid Eye Movement sleep, and frequent wakefulness are all linked to sleep problems. These are all common depression symptoms. Paroxetine(2) is an antidepressant that was made as a result of this rational medication development. This drugis a potent Selective Serotonin Reuptake Inhibitor (SSRI) that is authorized for the treatment of depression. It has a huge spectrum of effectiveness and has been authorized in a majority of countries for the treatment of OCD, panic disorder, and social phobia. The chemical messenger serotonin is boosted at the metalloproteinases level via SSRIs.In individuals with dysthymia, obsessive-compulsive disorder, social anxiety disorder (fear of social situation), premenstrual dysphoric disorder (PMDD), and raise of low self-esteem (confidence issues), paroxetine affects chemicals in the brain which may be sophisticated. Paroxetine is a chemical that is commonly authorized for depression, especially major depressive disorder. It works by aiding in the maintenance of a natural substance (serotonin) homeostasis in the brain. It's also been used to treat menopause-related hot flashes & premature ejaculation. Antistressisthe remedy that is used to heal mental health disorders. Various types of anti-stressare given below in Table-I

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1942-1947 www.ijprajournal.com ISSN: 2456-4494

TableI : Some antidepressants agents

NAMES OF THE DRUGS	STRUCTURE
PAROXETINE	
FLUOXETINE	
FLUVOXAMINE	
CLOMIPRAMINE	

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1942-1947 www.ijprajournal.com ISSN: 2456-4494

PHARMACOKINETICS:

Pharmacokinetics is defined as the branch of pharmacology concerned with the movement of drugs within the body(2). The main process of pharmacokinetics: Absorption, distribution, metabolism, excretion, and toxicity. There have been a variety of pharmacokinetic parameters represented. Additionally, there seems to be no interconnection between paroxetine vital fluid concentrations and acceptability or advancement.

ABSORPTION AND PLASMA CONCENTRATION:

During the time of absorption, paroxetine carries out multiple first-pass metabolisms, which have been estimated to be around 50% in the investigation in human trials(3). Due to the partial exhaustion of first-pass metabolism, paroxetine bioavailability is increased action after multiple doses after a single intake. Maximum plasma concentrations (Cmax) were almost a single portion of 5 to 15mg of the drug given by mouth to the healthy human case, with only achieve average mean time Cmax (t-max) of about 5 hours (range 0.5 to II hours). Paroxetine reached steady-state concentrations in one or two weeks, then after no cumulation of the drug was observed(4).

DISTRIBUTION:

Paroxetine's human gamma globulin binding has indeed been evaluated to be above 95%. On account of its, property of lipophilicity paroxetine can quickly flow through the tissues. In the region of 1% paroxetine stays in the system of circulation(5).

METABOLISM:

Paroxetine is processed extensively in the liver, where it is transformed into harmless glucuronide and sulfate metabolites. Approximately 2% of the main drug was removed in its entirety in the urinary system [6].



Figure 1: METABOLIC PATHWAY OF PAROXETINE IN HUMAN

ELIMINATION:

Paroxetine has such a strong and rather saturable first-pass effect due to its practically full metabolism. While estimated that approximately 1 or 2% of a drug intake is eliminated bythe urination process, a greater undivided portion is excreted in the form of paroxetine compounds through the excretory organ. The drug is processed in two phases, 1) first-pass (pre-systemic) metabolism and 2) dependent on systemic metabolic pathways. In a healthy subject, the average mean termination phase of half-life (t1/2) ofthe remedy looks to be almost 1day. The half-life of the drug was separate and separate individual human subjects have been observed and it varies daily doses of paroxetine 10

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1942-1947 www.ijprajournal.com ISSN: 2456-4494

to 40 mg for1 to 3 days after orally ingesting single and multiple(6).

TOLERABILITY/ ADVERSE REACTION:

In presymptomatic ideal, paroxetine was quite well abided by patients. The most common adverse events listed during short-term medication for one and half months are vomiting(16%), enervation (15%), transudation (8%), and inflexibility (13%), followed by myositis (8%), xerostomia [dry mouth] (9%), and insomnia (5%). Importantly, particularly in comparison to cyclic-antianxiety drugs, paroxetine induced much fewer antimuscarinic-type side effects (e.g., xerostomia, diarrhoea) and cardiac symptoms (e.g., postural hypotension, tachycardia)(7).

DOSAGE AND ADMINISTRATION:

Ina mature age person, anorderly dosage of 15 mg of the drug is guided. Within the medicated range of 20 to 50 mg/day, this may be rearrangedas needed, based on the patient's response and satisfactoriness. Paroxetine administered QD(once a day), with the meal, by morning. In geriatric patients, a maximum diurnal intake of 40 mg is endorsed. Concentrations should be limited to the lower end of the recommended range for treatment of renal or hepatic impairment(8).

RELATIONSHIP BETWEEN PLASMA CONCENTRATION AND CLINICAL EFFICACY:

On the topic of paroxetine, some researchers conducted a prospective analysis of 94 patients treated with 30 mg/day of oral paroxetine in phase III trials. Subjects' steady-state serum concentrations vary from 1 g/L to > 150 g/L, and there was no relationship between therapeutic potential and plasma concentration. In addition, no correspondence between the concentration of plasma and the frequency of inauspicious reactions to drugs(9).

PHARMACODYNAMIC:

Pharmacodynamics is defined as the branch of pharmacology concerned with the effects of drugs and the mechanism of their action(2).Paroxetine prevents serotonin reuptake by suppressing the active efflux pump pathway. Through such a negative feedback mechanism, blockage of serotonin reuptake leads to a reduction in neurotransmitter turnover. Depression is foresighted to be generated by abnormalities in the norepinephrine and/or cholecystokinin paths in the brain.

EFFECTS ON SEROTONINERGIC MECHANISMS

In the Central Nervous System:

A prominentand specific central serotonin uptake inhibitor, according to various in vitro&in-vivo animal experiments. Some researchers discovered that paroxetine generated dynamic and durably enhanced spondylosis caused by the serotonin pioneer, 5-hydroxytryptophan, in mice and rats (5-HTTP)(10). Other anti-depressant drugs either caused passable potential or were inactive, but paroxetine enhanced the antiseizure effects on 5-HTP.Theparoxetine for selective serotonin inhibition was further authorized after the combo of p-chloroamphetamine (PCA) [a spondylosis-inducing drug that inhibition ofserotonin reuptake was prevented].Paroxetine would not affect an effect on H 77/77-induced spondylosis, indicating that it has no effect on noradrenaline uptake in the brain. Paroxetine has a durable effect on serotonin reuptake inhibition(11). In mice, after a single intraperitoneal dose of 5 to 10mg/kg, 65 % inhibitory action was stayed for up to two days. In addition, rats received paroxetine 5 to 10mg/kg/day for approximately 1 to 2 weeks and demonstrated prolonged serotonin reuptake inhibitor(12).

Table II lists the mean inhibition constants (K_i values) for in vitro inhibition of serotonin and noradrenaline reuptake into rat hypothalamic synaptosomes, as well as the corresponding selectivityratios of several different antidepressant agents, including paroxetine.

Table II:Lists the mean inhibition constants (K_i values)

Drugs	**Mean uptake inhibition constant (K_i) [nmol/L]**		
	5-HT	**NA**	**NA/5-HT**
Paroxetine	1.1	350	320

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1942-1947 www.ijprajournal.com ISSN: 2456-4494

Citalopram	2.6	3900	1500
Fluvoxamine	6.2	1100	180
Fluoxetine	25	500	20

However, paroxetine is the most specific inhibitor of serotonin reuptake, with just a Ki of 1.1 nmol/L compared to citalopram's Ki of 2.6 nmol/L.

EFFECTS ON NORADRENALINE (NOREPINEPHRINE) AND OTHERNEUROTRANSMITTERS:

Paroxetine almost has no closeness for the sympathetic nervous system or other neurotransmitteramine uptake inhibition(13). In addition, paroxetine decreased spondylosis triggered by serotonin mechanisms in rats. The strength of the drug to keep under control serotonin and norepinephrinetaking up into rat hypothalamus synaptosomes in vitro was differentiatedfrom that of amitriptyline, clomipramine, and imipramine by measuring the drug concentration required to achieve 50% inhibitory action(14). They discovered that 0.4, 200, and 1000 nmol/L of paroxetine were required to inhibit fifty percent uptake of radioactively labeled serotonin, dopamine, and histamine into rat synaptosomes, respectively(15).

CENTRAL NERVOUS SYSTEM EFFECTS:

Unlike cyclic antianxiety drugs, which already have tranquilizing properties overdue to their antimuscarinic activity, electroencephalographic (EEG) tests in animals and people indicatethis drug does not induce sedation(16). The drug-inducedrest in rats just be slow down, and when it occurs in sleep, it was fair and lacked the rapid eye movement (REM) phase. In depressed people, cyclic antianxiety drugs tend to resume patterns of sleep, potentially via changing the mechanism of serotonin in sleep modulation. The effects of morning and evening administrations of paroxetine 30mg on sleep parameters were examined in a study of healthy participants with autogenous depression using a sub-analysis of dissimilarities in Hamilton Depression Rating Scale variables related to sleep and the Leeds Sleep Evaluation Questionnaire. Dosages of paroxetine resulted in remarkable improvements in 5 of 12scrutinize parameters from one and half months by morning. As a result of these issues, it was determined that paroxetine should be taken first thing in the morning.
During medical studies, the prevalence of insomnia linked with paroxetine was 6% with short-term treatment and 8% with long-term treatment, though there was no correlation between reports of sleep disruption and Paxil administration time(17).

CARDIOVASCULAR EFFECTS:

Hypoxaemia&cardiac function interruptionis recognized disadvantageous effects of cyclic antianxiety drugs. The finding that paroxetine is absolute to the complex transporter of serotonin reuptake but has little effect on other receptor sites might explain the drug's lower cardiac effects in animal models and human studies of patients without cardiac disease(18). In anawake rabbit and a sedative cat, when the heart effects of paroxetine and amitriptyline were differentiated and it has shown significant changes in hypertension, pulsation, and electrocardiographic area required intravenous infusions of paroxetine just around 2 to 4 times greater than those of amitriptyline. Pulse, blood pressure, and electrocardiographic parameters were not altered by paroxetine 30 to 40 mg/day(19).

DRUG INTERACTION:

Alcohol, haloperidol, and lorazepam, along with other central nervous system depressants, are not enhanced by paroxetine. There is an elevated pharmacokinetic interaction because they areinhibitors of the cytochrome P450 2D6 enzyme. Paroxetine plasma levels may rise or drop when mixed with an enzyme inhibitor like cimetidine or an enzyme inducer like phenobarbital or phenytoin.

II. CONCLUSION:

In this review article, paroxetine the principal concepts of clinical pharmacology have been expressed. This paroxetine has good pharmacokinetic parameters such as absorption, distribution, metabolism, elimination, and toxicity, and pharmacodynamic works on the central nervous system.

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 1942-1947 www.ijprajournal.com ISSN: 2456-4494

REFERENCE:

[1]. https://en.wikipedia.org/wiki/Depression_(mood)
[2]. K.L. Dechant, Paroxetine,A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness, 225-53,1991.
[3]. Greb WH, Brett MA, Buscher G, Dierdorf HD, von Schrader HW, et al. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiatrica Scandinavica 80 (350): 99-101, 1989a
[4]. Lund J. Lomholt B. Fabricius J. Christensen JA. Bechgaard E. The pharmacokinetics and the effect on blood 5-HT of paroxetine in man. Nordisk PsykiatriskTidsskrift 33 (6): 450-454. 1979.
[5]. Kaye CM. Haddock RE. Langley PF. Mellows G. Tasker TCG.et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatrica Scandinavica 80 (350):60-75. 1989.
[6]. Haddock RE, Johnson AM, Langley PF. Nelson DR, Pope JA, et al. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites.ActaPsychiatrica Scandinavica 80 (350): 24-26, 1989.
[7]. Hebenstreit GF. Fellerer K. Z6chling R. Zentz A. Dunbar Gc. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatrica Scandinavica 80 (350): 81-84. 1989.
[8]. Hamilton TC, Norton J, Poyser RH, Thormahlen D. Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals. Arzneimittel-Forschung 36: 460-463, 1986.
[9]. Tasker TCG, Kaye CM, Zussman BD. Link CGG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events.ActaPsychiatrica et Scandinavica 80 (350): 152-155, 1989.
[10]. BuusLassen J. Potent and long-lasting potentiation of two 5-hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitors. European Journal of Pharmacology 47:351-358, 1978a.
[11]. Magnussen I. Tender K. Engbaek F. Paroxetine. a potent selective long-acting inhibitor of synaptosomal 5-HT uptake in mice. Journal of Neural Transmission 55: 217-226. 1982.
[12]. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93: 193-200, 1987.
[13]. BuusLassen J. Influence of the new 5HT-uptake inhibitor paroxetine on hypermotility in rats produced by p-chloroamphetamine (PC A) and 4, -dimethyl-m-tyramine (H77/77). Psychopharmacology 57 (2): 151-153, 1978b.
[14]. Johnson AM. Nelson DR. Thomas DR. Effect of paroxetine and other 5 hydroxytryptamine uptake inhibitors on central monoamine uptake in vitro and ex vivo. British Journal of Pharmacology (Suppl.): 221 P. 1985.
[15]. Tanigaki N, Manno K, Sugihara K. Miki N, Ichida S. et al. Abstract.Specific inhibitory action of the novel antidepressant paroxetine on 5-HT uptake. Folia Pharmacologica Japonica89: 175- 180. 1987.
[16]. Watanabe S, Ohta H, Ohno M. Tani Y, Furuya Y. et al. Electroencephalographiceffects of the new antidepressant paroxetinein the rabbit. Arzneimittel-Forschung 38: 332-340, 1988.
[17]. Borzeix MG, Berbey B, Cahn J. The EEG profile of paroxetinein the rat. In Bes A. (Ed.) Senile dementi as: early detection,pp. 424-429, John Libbey Eurotext, 1986.
[18]. Blackwell B. Adverse effects of antidepressant drugs. Part I:Monoamine oxidase inhibitors and tricyclics. Drugs 21: 201-219, 1981.
[19]. Hamilton TC, Norton J, Poyser RH, Thormahlen D. Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals. Arzneimittel-Forschung 36: 460-463, 1986.